Comparative Pharmacology
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus ESTRADIOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus ESTRADIOL.
DIETHYLSTILBESTROL vs ESTRADIOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen that binds to estrogen receptors (ERα/ERβ), activating estrogen-responsive gene transcription, leading to proliferation of estrogen-sensitive tissues.
Estradiol acts by binding to estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and cellular effects. It influences reproductive tissues, bone density, cardiovascular system, and central nervous system.
0.5-2 mg orally once daily for palliative treatment of advanced prostate cancer; 5-15 mg orally once daily for prevention of postpartum breast engorgement.
Oral: 1-2 mg daily; Transdermal: 0.025-0.1 mg/day applied twice weekly; Topical gel: 0.75-1.25 mg daily; Vaginal: 0.5-2 mg daily depending on formulation.
None Documented
None Documented
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in adults; prolonged in hepatic impairment.
Terminal elimination half-life: 13-20 hours (oral micronized); 36-48 hours (transdermal). Clinical context: supports once-daily oral or twice-weekly transdermal dosing.
Primarily renal (90% as glucuronide and sulfate conjugates), with less than 5% excreted unchanged in urine; biliary/fecal elimination accounts for about 10%.
Renal (50-80% as glucuronide and sulfate conjugates), biliary/fecal (10-30%), <5% unchanged.
Category C
Category D/X
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."